Topic Listing for OSI Pharmaceuticals

Accruals Clinical Research Organization Site Costs Acquired In-process Research Development
Although Clinical Candidates Pipeline Oncology Diabetes Obesity Appear Although Clinical Pre-clinical Candidates Pipeline Oncology Diabetes Obesity
Amended 2007 Amended 2009
Amortization Intangibles Anker Lundemose Phd Dsc
Annual Interim Retainer Fees Annual Retainer Fee
Approval Amendment Amended Restated Stock Incentive Plan Assets
Audit Committee Charter Audit Non-audit Fees
Available Information Balance 2004
Balance 2005 Balance 2006
Base Salary Beneficial Ownership Reporting Compliance
Benefits Benefits Perquisites
Business Increasingly Affected Pressures Drug Pricing Limit Reduce Cannot Successfully Protect Exploit Enforce Intellectual Property Rights
Cash Bonuses Cash Retainer
Ceo Cfo Certifications Change
Changes Internal Controls Over Financial Reporting Changes Laws Regulations Accepted Clinical Procedures Social Pressures
Clinical Development Programs Colin Goddard Phd
Collaboration Pfizer Collaborative Development Programs Pfizer
Collaborative Partners Required Obtain Licenses Parties Revenues Royalties Collaborative Profit Share
Collaborative Program Revenues Collaborative Revenue
Collaborators Required Obtain Licenses Parties Revenues Royalties Commercialized Commitments Contingencies
Compensation Committee Policy Regarding Change Control Severance Payments Compensation Committee Report
Compensation Discussion Analysis Competition
Competitors Challenge Patents Anda 505 New Drug Application Competitors Succeed Developing Products Technologies Effective Own Scientific
Compliance Rule 16b-3 Contacts
Cost Goods Sold Date
Deductibility Cap Executive Compensation Deferred Compensation Plan
Depend Heavily Principal Marketed Product Tarceva Generate Revenues Description
Diabetes Obesity Clinical Programs Discovery Research Diabetes Obesity Discovery
Distribution Pricing Divestiture Eye Disease Business
Documents Incorporated Reference Dpiv Outlicensing Program
Election Directors Employees
Employment Agreement Pierre Legault Employment Agreements Named Executive Officers
Equity Equity Awards
Equity Compensation Plan Information 2006 Equity Compensation Plan Information 2008
Evaluation Disclosure Controls Procedures Exact Name Registrant Specified Charter
Executive Compensation Policies Executive Compensation Policy
Executive Compensation Process Executive Officers
Expense Expenses
Extraordinary Gain Failure Prevail Litigation Costs Including Patent Infringement Claims
Fair Value Fda Approval Process
Fold Detach Here Foreign Government Involvement Control Over Pricing Pharmaceutical Products
Form 10-k Forward Looking Statements
Future Legislative Regulatory Reform Healthcare System Limit Commercial Gabriel Leung
Global Credit Financial Market Conditions Negatively Impact Value Goodwill Other Long-lived Assets
Governance Documents State Law Provide Certain Anti-takeover Measures Government Agencies Not Grant Collaborative Partners Required Approvals
Government Agencies Not Grant Collaborators Required Approvals Potential Grant Plan-based Awards
Grant Plan-based Awards 2007 Hatch-waxman Act
Holders Dividends Http Wwwosipcom
Http Wwwsecgov Impairment Intangible Asset
Impairment Intangible Assets Important
Income Taxes Independent Compensation Consultant
Intellectual Property Inventory
Investigator Sponsored Studies Investments Other-than-temporary Impairments
Key Fda Regulations License Fees Milestones
License Milestone Other Revenues Lifecycle Plan
Liquidity Capital Resources List Appendices
Low Managements Report Internal Control Over Financial Reporting
Manufacturing Manufacturing Supply
Market Information Medicare Prescription Drug Coverage Legislation Improvement Modernization
Meetings Melville New York 8211november 2009
Michael Atieh Nasdaq Stock Market Llc
Net Revenue Expense Unconsolidated Joint Business Net Revenue Unconsolidated Joint Business
Net Revenues Unconsolidated Joint Business News Release
Not Able Make Required Payments Interest Principal Indebtedness Not Able Successfully Obtain Grant Tarceva Patent Reissue
Not Receive Adequate Third-party Reimbursement Sales Marketed Products Not Receive Adequate Third-party Reimbursement Sales Tarceva See
Not Receive Timely Accurate Financial Information Genentech Roche Notice Annual Meeting Stockholders
Novantrone Number
Oncology Diabetes Obesity Discovery Efforts Oncology Research
Oncology Research Development Strategy Programs Operating Results Adversely Affected Fluctuations Value Dollar Against
Option Exercises Stock Vested Option Exercises Stock Vested 2006
Option Exercises Stock Vested 2007 Option Exercises Stock Vested 2008
Option Grants Other Stock Awards Option Grants Restricted Stock Awards
Options Exercisable Osi Genentech Roche Alliance
Osi Pharmaceuticals Osi Pharmaceuticals Inc
Other Development Programs Significant Outlicensing Activities Other Income Expense
Other Information Regarding Directors Other Intellectual Property
Other Macugen Clinical Programs Other Matters
Other Payments Other Regulation
Other Revenues Other Significant Commitments Contingencies Include Following
Outlicensing Certain Clinical Programs Outstanding Equity Awards End
Oversight Executive Compensation Program Overview
Part Patents Adversely Affected Changes Patent-related Statutes Rules Patent
Paul Chaney Perquisites
Pierre Legault Pinelawn Road Melville
Plan Plans
Post-retirement Medical Benefits Potential Payments Termination Change Control
Potential Payments Termination Change-in-control Potential Products Clinical Trials Sale Approved Exposes Liability
Pricing Reimbursement Product Sales
Proxy Solicited Behalf Osi Pharmaceuticals Incs Board Directors Proxy Statement
Ratification Appointment Independent Registered Public Accounting Firm Reliance Parties Such Clinical Research Organizations Cros Manufacturers
Reliance Parties Such Clinical Research Organizations Cros Result Report Audit Committee
Report Independent Registered Public Accounting Firm Consolidated Financial Report Independent Registered Public Accounting Firm Internal Control
Research Development Responsibilities Duties
Results Operations Revenues
Revenues Dpiv Patent Portfolio Licenses Contingent Ability Licensees Review Total Compensation Peer Group
Risks Related Common Stock Risks Related Intellectual Property Legal Matters
Robert Simon Royalties
Royalties Product Sales Sales Commissions
Sales Marketing Securities Exchange Act 1934
Selling General Administrative Severance Benefits
Share Ownership Requirements Share Retention Guidelines Hedging Prohibition
Share Retention Guidelines Prohibition Hedging Pledging Stock Ownership Signatures
Some Activities Subject Risks Federal State Laws Prohibiting Starting 2008 Generic Competitors Challenge Patents Filing Anda
Stock Price Remains Highly Volatile Make Difficult Stockholders Stock-based Compensation
Stockholder Proposals Strategy
Studies Combine Tarceva Other Targeted Agents Studies Expand Tarceva Other Nsclc Treatment Areas
Studies Expand Tarceva Other Pancreatic Cancer Treatment Areas Summary Compensation Table
Tarceva Become Subject Problems Related Efficacy Safety Otherwise Tarceva Imported United States Japan Countries Cost Drug
Tarceva-related Intellectual Property Tarceva-related Milestones
Tarceva-related Revenues Tarceva-related Royalties
Three-month Transition Period Title Class
Transition Period Unable Protect Confidentiality Proprietary Information Know-how Value Technology
Zip Code 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki